

This material is an English translation of the press release announced on July 18, 2017 in Japanese, and the Japanese release is given priority about the content and the interpretation.

---

July 18, 2017

**Notification of the commencement of the Phase III clinical study of HP-3150 in Japan for  
“cancer pain” (an analgesic transdermal drug containing NSAIDs)**

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga prefecture, Japan; Chairman and CEO: Hirotaka Nakatomi, hereinafter referred to as Hisamitsu) hereby announces that it has commenced of the Phase III clinical study for “cancer pain” in Japan for an analgesic transdermal patch containing NSAIDs (Development code: HP-3150, hereinafter referred to as “the product”).

In the Phase III clinical study, the efficacy and safety of administration of the product once per day will be compared with a placebo in patients suffering from cancer pain. We expect the product to be a new option for the treatment of such patients who will benefit from its long-lasting effect by means of maintaining a stable blood concentration.

The product is a systemic transdermal drug developed utilizing Hisamitsu’s TDDS (Transdermal Drug Delivery System) technology and containing the active ingredient NSAIDs (Non-Steroidal Anti-Inflammatory Drugs).

We aim to apply for manufacturing and marketing approval during FY 2020.



## **Delivering Patch Culture Hand by Hand**

Hisamitsu Pharmaceutical Co., Inc. was established in 1847 and has marked its 170th anniversary since its foundation thanks to the support of many people.